Reviews:
Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets
Metrics: PDF 1913 views | HTML 3611 views | ?
Abstract
Ya-Hui Ding1,3, Yuan Ma1,3, Lin-Yan Qian1,3, Qiang Xu1,3, Li-Hong Wang1,3, Dong-Sheng Huang2,3 and Hai Zou1,3
1Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
2Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital, Hangzhou 310014, China
3People’s Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Correspondence to:
Qiang Xu, email: [email protected]
Li-Hong Wang, email: [email protected]
Dong-Sheng Huang, email: [email protected]
Hai Zou, email: [email protected]
Keywords: non-alcoholic fatty liver disease, atrial fibrillation, adiponectin, insulin resistance, renin angiotensin aldosterone system
Received: May 23, 2017 Accepted: July 13, 2017 Published: July 24, 2017
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) and atrial fibrillation (AF) are common chronic non-infectious diseases with rising incidences. NAFLD is an independent risk factor for the onset of AF, after adjusting potentially related factors. The pathogenesis of these diseases share several mechanisms including reduced adiponectin level, insulin resistance, and renin angiotensin aldosterone system (RAAS) activation, in addition to activation of common disease pathways that promote inflammation, oxidative stress, and fibrosis. Furthermore, statins and RAAS blockers exert therapeutic effects concurrently on NAFLD and AF. The common pathogenesis of NAFLD and AF may serve as a potential therapeutic target in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19522